June 2018 Vol. 6 No.6

Abstract
• Full text
•Reprint (PDF) (493 KB)

Search Pubmed for articles by:
 

Original Research Article

Assessment of neuroendocrine markers in different molecular subtypes of invasive breast carcinoma and its impact on prognosis

Shaimaa M. Yussif^1* and Nahed Soliman²

¹Department of Pathology, Faculty of Medicine, University of Mansoura, Mansoura, Egypt
²Department of Pathology, Faculty of Medicine, University of Helwan, Egypt

*Corresponding Author’s E-mail: shimo.yussif@yahoo.com

Accepted May 28, 2018

Abstract

Neuroendocrine differentiation has been detected in many histologic types of breast carcinoma, including invasive ductal, lobular, colloid, or papillary carcinoma and even insitu carcinoma. This study detected the immunohistochemical expression of neuroendocrine markers in invasive breast carcinoma molecular subtypes and its impact on prognosis. Also their relation to other clinicopathological factors was also analyzed. 242 cases of invasive breast carcinoma were assembled retrospectively from Mansoura University, Faculty of Medicine, Oncology Center, Egypt between 2010 and 2012. IHC FOR ER, PR, Her2neu, ki67 were done for molecular subtyping. Synaptophysin, chromogranin and CD56 were stained and recorded then assessment of the relationship between them and different clinicopathological parameters was done. Chromogranin A and synaptophysin, positivity were statistically associated with invasive breast carcinoma molecular subtypes (P value 0.007, 0.01 respectively) while CD56 was not (p value 0.9). Chromogranin A positivity showed significant association with tumor grade, histological subtype, molecular subtype, patient outcome death, and recurrence or metastasis (P values of 0.04, 0.00, 0.007, 0.005, 0.009 respectively). Synaptophysin positivity showed significant association with tumor grade, molecular subtype, patient outcome (death, and recurrence or metastasis) (P values of 0.04, 0.01, 0.01, 0.002 respectively). Neuroendocrine differentiation is more commonly associated with luminal B subtype which usually has poorer prognosis, higher tumor grades and better chemotherapeutic response than luminal A. More studies are required to understand the relationship of luminal B subtype and neuroendocrine differentiation.

Keywords: Neuroendocrine markers, molecular subtypes, breast carcinoma, prognosis